Lawrence Livermore National Laboratory Covid-19 Therapeutic Design
Therapeutic leads for SARS-CoV-2: in silico predictions and selected experimental validation for public small molecule libraries and designed synthetic antibodies.
Query small molecule drug design results against four SARS-CoV-2 targets
Current compound set: 19589386.
Learn more » LLNL COVID-19 Research and Response »